Current Updates
RXR Agonists

 RXR article published in Diabetology & Metabolic Syndrome, Aug 2014

Current Updates
11HSDbeta1 Inhibitor

HSD article published in BMC Pharmacology and Toxicology, Aug 2014

Current Updates
ADA 2014

Connexios presented new data on CNX-013-B2, a pan-PPAR RXR agonist at ADA's 74th Scientific Sessions

Current Updates
AMPK Activators

Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators

Click

About us

News & Events

Next GENERATION therapies

About Us

Connexios is a venture-backed company established in 2003. We are building a broad innovative clinical pipeline that aims to address the critical clinical gaps in Type 2 Diabetes and related metabolic diseases. Our expertise in the metabolic diseases space is based on our proprietary Network Biology platform that enables us to link the cellular and molecular events and processes.

more

News & Events

  • 12 AUG CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models
  • 13 JUN CNX-013-B2, a PPAR Pan-Activator Rexinoid, Provides Robust Control of Glucose, HbA1c, Triglyceride, and LDL Cholesterol in db/db Mice and Does Not Cause Hemodilution and Edema in Rodents
more

Next Generation Therapies

We beleive that effective therapies have to engage with dysregulations in cell function and outcomes across different tissues in order to provide a robust therapeutic impact.

This is practically true in case of chronic, systemic and multifactorial diseases like T2D.

more